Abstract Matrix metalloproteinase‐9 (MMP‐9) is a member of the metzincin family of mostly
extracellularly operating proteases. Despite the fact that all of these enzymes might be target …

Background Treatment of mild-moderate Alzheimer's disease (AD) subjects (N= 119) for 52
weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates …

Although matrix metalloproteinases (MMPs) are implicated in the regulation of numerous
physiological processes, evidence of their pathological roles have also been obtained in the …

Major depressive disorder is a complex disease resulting from aberrant synaptic plasticity
that may be caused by abnormal serotonergic signaling. Using a combination of behavioral …

Fragile X syndrome (FXS) is a leading genetic cause of autism with symptoms that include
sensory processing deficits. In both humans with FXS and a mouse model [Fmr1 knockout …

Matrix metalloproteinase 9 is a proteolytic enzyme which is recently one of the more often
studied biomarkers. Its possible use as a biomarker of neuronal damage in stroke, heart …

The sensitivity of ocular dominance to regulation by monocular deprivation is the canonical
model of plasticity confined to a critical period. However, we have previously shown that …

The assembly and maturation of the mammalian brain result from an intricate cascade of
highly coordinated developmental events, such as cell proliferation, migration, and …

Abstract Models of firing rate homeostasis such as synaptic scaling and the sliding synaptic
plasticity modification threshold predict that decreasing neuronal activity (for example, by …

Long-term synaptic plasticity is shaped by the controlled reorganization of the synaptic
proteome. A key component of this process is local proteolysis performed by the family of …